alpha-1 antitrypsin-associated liver disease

Takeda Signs ~$1B Pact with Arrowhead for ARO-AAT Targeting Alpha-1 Antitrypsin-Associated Liver Disease

Shots: Arrowhead to receive ~$300M up front, ~$740M as development, regulatory and commercial milestones and is eligible to receive royalties of 20-25% on net sales If approved, the companies will co-develop ARO-AAT and co-commercialize it in the US, under 50/50 profit sharing structure. Additionally, Takeda will lead the global commercialization strategy and get an exclusive …

Takeda Signs ~$1B Pact with Arrowhead for ARO-AAT Targeting Alpha-1 Antitrypsin-Associated Liver Disease Read More »

Takeda strikes $1B RNAi deal with Arrowhead Pharmaceuticals

The companies will partner on development and commercialization of ARO-AAT, Arrowhead’s Phase II RNA-interference drug for alpha-1 antitrypsin-associated liver disease, a rare genetic disorder. An analyst wrote that the deal makes sense given Takeda’s position in the AAT-augmentation therapy market.